Tempest Therapeutics received a notice from Nasdaq that its common stock closed below $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until May 3, 2027, to restore the bid price to at least $1.00 for ten consecutive trading days. Failure to comply may result in delisting proceedings or a required reverse stock split. Tempest Therapeutics operates in the biotechnology sector.
